Gene Prediction Tools Market Size, Share & Trends Analysis Report By Component (Software, Services), By Method (Ab- initio Prediction, Homology-based Prediction, Hybrid Gene Prediction), By Application (Diagnostics, Drug Discovery & Designing, Others), By End-User (Pharmaceuticals & Biotechnology Companies, Diagnostics Centers, Academic & Research Institutes, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Gene Prediction Tools Market Size

The global gene prediction tools market size was valued at USD 206.31 million in 2024 and is projected to grow from USD 248.13 million in 2025 to reach USD 582.64 million by 2033, exhibiting a CAGR of 11.3% during the forecast period (2025-2033).

Gene prediction tools are bioinformatics software designed to identify genes within a given DNA sequence. These tools use computational algorithms to analyze genomic data, detect coding regions, and predict gene structures, including exons, introns, and regulatory elements. They rely on various approaches, such as ab initio methods, which use statistical models to identify genes based on sequence patterns, and homology-based methods, which compare sequences to known genes in databases.

A significant trend shaping the market is the growing adoption of cloud-based bioinformatics solutions, which enable efficient genomic data analysis with improved accessibility and scalability. Moreover, the integration of AI and machine learning (ML) into gene prediction is revolutionizing genome annotation by enhancing accuracy, streamlining workflows, and significantly reducing the time required for analysis.

A notable advancement in this space came in September 2023, when Deep Genomics introduced BigRNA, an AI-driven foundation model designed to enhance gene prediction. BigRNA accurately identifies tissue-specific RNA regulatory mechanisms, protein and microRNA binding sites, and the effects of genetic variants. This breakthrough strengthens the market by facilitating precise genomic analysis, accelerating the discovery of novel therapeutic targets, and advancing RNA-based drug development.

Beyond healthcare, agricultural and livestock genomics are emerging as new growth avenues, with gene prediction tools playing a crucial role in crop improvement and disease resistance. Government initiatives and funding, such as the Human Genome Project and Genome India Initiative, are further driving innovation. Moreover, strategic collaborations between biotech firms and AI-driven genomic analysis companies are expanding market opportunities, fostering innovation, and accelerating the adoption of advanced gene prediction technologies.

Gene Prediction Tools Market Trends

Rising adoption of AI & machine learning in genomics

The integration of Artificial Intelligence (AI) and Machine Learning (ML) in genomics is transforming gene prediction, variant analysis, and disease risk assessment. AI-powered algorithms improve the accuracy and efficiency of genomic sequencing, enabling faster identification of genetic markers and potential therapeutic targets. ML models analyze vast genomic datasets to uncover patterns, accelerating drug discovery and precision medicine.

• For instance, in November 2024, an article published in the National Library of Medicine highlighted the development of Evo, a genomic AI model trained on millions of microbial and viral genomes. Evo excels in predicting gene functions, designing novel CRISPR-Cas systems, and simulating genomic architectures. This breakthrough significantly advances AI-driven genomic research, enhancing applications in gene editing, mutation analysis, and synthetic biology.

Such advancements highlight the transformative potential of AI and ML in genomics, paving the way for more precise diagnostics, innovative therapies, and a deeper understanding of genetic diseases.

Growing demand for personalized medicine

Rising government funding and initiatives are advancing genomic research through national genome projects, precision medicine programs, and biobank collaborations. These efforts enhance sequencing infrastructure, innovation, and personalized healthcare solutions, driving the adoption of gene prediction tools.

• For instance, in October 2022, Illumina Inc. announced a strategic research collaboration with AstraZeneca to accelerate drug target discovery. By combining AI-driven genome interpretation with advanced genomic analysis, the partnership aims to enhance target identification and advance drug development using human omics insights.

The growing focus on personalized medicine is transforming healthcare, enabling more precise treatments, improved patient outcomes, and the development of next-generation therapeutics.

Gene Prediction Tools Market Driving Factors

Government initiatives & funding for genomic research

Rising government funding and initiatives are advancing genomic research through national genome projects, precision medicine programs, and biobank collaborations. These efforts enhance sequencing infrastructure, innovation, and personalized healthcare solutions, driving the adoption of gene prediction tools.

• For instance, in September 2022, the CDC announced USD 90 million in funding to establish the Pathogen Genomics Centres of Excellence (PGCoE) network. This initiative aims to enhance genomic surveillance, disease tracking, and public health responses by integrating advanced gene prediction tools and sequencing technologies.

Such investments are accelerating genomic innovations, paving the way for improved disease prevention, early diagnostics, and the advancement of precision medicine, driving the market.

Rising prevalence of genetic disorders

The increasing incidence of genetic disorders is driving the demand for gene prediction tools to enable early diagnosis, risk assessment, and targeted treatments. Conditions such as cancer, cystic fibrosis, and rare hereditary diseases are fuelling research in genomic sequencing and predictive analytics.

• For instance, in January 2024, the American Cancer Society projected that the U.S. will record approximately 2 million new cancer cases and over 611,000 cancer-related deaths, emphasizing the urgent need for early detection and targeted treatments. Advances in gene prediction tools are playing a crucial role in cancer genomics, facilitating early diagnosis, risk assessment, and personalized therapies, ultimately improving patient outcomes.

The prevalence of genetic disorders continues to rise, driving the need for advanced gene prediction tools to become even more critical to enable early intervention, accurate diagnostics, and effective treatment strategies, driving market growth.

Market Restraining Factors

High costs of gene prediction & genomic analysis

The high costs of gene prediction tools and genomic analysis present a major barrier to widespread adoption. Advanced technologies, powerful computational infrastructure, and specialized expertise drive up expenses, making it challenging for smaller research institutions and biotech firms to access these tools. Moreover, whole genome sequencing, data storage, and bioinformatics analysis require significant financial investment, further restricting scalability. Healthcare providers also face cost constraints, limiting the integration of gene prediction tools in clinical practice. Without cost-effective solutions, the potential benefits of genomic research and personalized medicine remain difficult to achieve on a broader scale.

Market Opportunity

Development of user-friendly gene prediction software

The demand for user-friendly gene prediction software is rising as researchers and healthcare professionals seek accessible, automated, and intuitive tools for genomic analysis. Advances in AI-powered interfaces, cloud-based platforms, and no-code bioinformatics solutions are enhancing usability, reducing reliance on specialized expertise, and accelerating genomic research.

• For instance, in June 2022, according to an article published in the National Library of Medicine, researchers introduced PhenGenVar, a user-friendly tool for detecting and visualizing genetic variants linked to specific diseases and phenotypes. The tool enables flexible filtering and browsing of variants in genes of interest, facilitating molecular diagnosis.

Such innovations enable wider adoption in clinical diagnostics, drug discovery, and personalized medicine, expanding the market for gene prediction tools.

Regional Insights

North America: Dominant region with 38.7% market share

North America dominates the gene prediction tools market, driven by substantial investments in genomics research, advanced bioinformatics infrastructure, and robust government funding initiatives. The presence of key players like Illumina, Thermo Fisher Scientific, and Pacific Biosciences strengthens regional growth. Moreover, strategic collaborations between biotech firms, research institutions, and AI companies enhance innovation. The increasing integration of machine learning in genomic analysis, rising adoption of precision medicine, and expanding applications in oncology, rare disease diagnostics, and drug discovery further solidify North America’s leadership in the market.

Asia Pacific: Fastest growing region with the highest market CAGR

Asia-Pacific is expected to hold the highest CAGR, driven by increasing genome sequencing initiatives, rising healthcare expenditures, and rapid advancements in precision medicine. Countries like China, India, and Japan are heavily investing in large-scale genomic research projects such as the Genome India Initiative and China’s Precision Medicine Initiative. Moreover, the emergence of local bioinformatics startups, government-backed funding programs, and partnerships with global biotech firms are accelerating market expansion. Growing demand for genetic diagnostics, personalized medicine, and AI-powered genomic tools further propels Asia-Pacific’s rapid market growth.

Countries Insights

• U.S.- The U.S. gene prediction tools market is a leader due to its substantial government funding, strong presence of biotechnology and pharmaceutical companies, and high adoption of AI-driven bioinformatics. The country’s focus on precision medicine, genomic research programs, and strategic collaborations between academic institutions, healthcare providers, and tech firms drives continuous innovation, strengthening its position in the market.
• Germany- Germany is one of the largest market for gene prediction tools in Europe, driven by the expansion of new facilities and an increase in government funds and initiatives. For instance, in March 2024, Roche received a €90 million investment under Germany’s National Strategy for Gene and Cell Therapies to establish a gene therapy center. The facility will focus on manufacturing gene therapy vectors for clinical trials, advancing research and development in the field.
• UK- The United Kingdom’s market, is driven by significant government investments in genomics research. For instance, in December 2022, the UK government announced over £175 million in funding to advance genomics research. This initiative aims to develop the most advanced genomic healthcare system, enhancing disease prevention, early diagnosis, and personalized treatments to improve health outcomes in the country.
• Canada– Canada's gene prediction tools industry is expanding due to government-backed genomic research initiatives. In October 2023, the Canadian government announced a $15 million investment to create the Pan-Canadian Genome Library aimed at seamless genomic data sharing. Supported by the Canadian Institutes of Health Research, this initiative boosts rare disease research, precision medicine advancements, and the development of genetic therapies, positioning Canada as a key player.
• India– India’s gene prediction tools market is witnessing rapid growth, driven by expanding research facilities, increasing biotech investments, and government-backed initiatives. In August 2023, Illumina Inc. launched the Illumina Solutions Centre in Bengaluru, designed to enhance sequencing capabilities, support genomic research, and foster industry collaborations. India's focus on genetic diagnostics, personalized medicine, and bioinformatics innovation is accelerating market expansion, making it a rising global hub for genomic research and precision medicine.
• China- China’s market for gene prediction tools is experiencing significant growth, supported by strong government initiatives, rising research investments, and expanding genomic sequencing capabilities. The country’s emphasis on precision medicine, biotechnology innovation, and large-scale genome projects, such as the China Precision Medicine Initiative, is driving adoption. Moreover, China's growing bioinformatics sector, AI-powered genetic analysis, and increasing demand for personalized healthcare solutions are accelerating advancements in genomic research and medical applications.

Segmentation Analysis

The global gene prediction tools market is segmented into component, method, application, and end-user.

By Component

The software segment dominates the market due to the growing adoption of AI-driven algorithms, which enhance predictive accuracy and streamline genomic analysis. These provide automation, seamless integration with genomic databases, and scalability, making them essential for researchers, biotech firms, and pharmaceutical companies. Moreover, the rise of cloud-based bioinformatics platforms and open-source genomic software is driving further adoption by enabling cost-effective and accessible genomic research.

By Method

Ab-initio prediction dominates the global market due to its ability to analyse unknown genomic sequences without requiring prior knowledge, making it valuable for novel gene discovery. It is widely used in computational genomics and genome annotation projects. Moreover, advancements in AI and machine learning are further enhancing the accuracy and efficiency of ab-initio gene prediction models, driving their continued adoption in genomics research and personalized medicine.

By Application

The diagnostics segment dominates the market, driven by its increasing use in detecting genetic disorders, cancer biomarkers, and inherited diseases. The growing demand for precision medicine and early disease detection fuels adoption in clinical settings. Moreover, advancements in next-generation sequencing (NGS) and bioinformatics enhance diagnostic accuracy, supporting applications in newborn screening, rare disease identification, and predictive genetic testing for personalized treatment plans.

By End-User

Pharmaceutical & biotechnology companies dominate the market due to the increasing use of gene prediction tools in drug discovery, genetic therapy research, and biomarker identification. These companies leverage predictive genomics to enhance targeted therapies and streamline clinical trials. Moreover, strategic collaborations between biotech firms, research institutions, and AI companies are accelerating advancements in genomic research, fostering innovation in gene-based therapies and personalized treatment approaches.

Company Market Share

Key players in the market are actively adopting strategic collaborations, product approvals, acquisitions, and product launches to strengthen their market presence. Companies are investing in AI-driven bioinformatics solutions, expanding genomic databases, and integrating machine learning algorithms to enhance predictive accuracy.

Verily: An emerging player in the global gene prediction tools market

Verily Life Sciences, a subsidiary of Alphabet Inc., focuses on applying data science, artificial intelligence, and biomedical research to advance precision medicine and healthcare solutions. Verily is leveraging AI-driven genomic analysis, cloud-based research platforms, and strategic collaborations to enhance gene identification and biomarker discovery.

Recent developments by Verily:

• In October 2023, Verily launched viewpoint workbench, a secure platform for unifying multimodal data and accelerating genomic research. Part of Verily Viewpoint, it enhances gene prediction tools by enabling efficient data governance and analysis, supporting biopharma and precision medicine advancements.

Recent Developments

• March 2024 – insitro, a machine learning-driven drug discovery company, collaborated with Genomics England to integrate machine learning-powered embedding search capabilities into Genomics England’s multimodal phenotypic and genetic database. This partnership aims to enhance genomic data analysis, improving drug discovery and precision medicine.
• January 2025 – Illumina, Inc. announced a collaboration with NVIDIA to enhance technology platforms for multiomic data analysis and interpretation. This partnership aims to accelerate advancements in clinical research, genomics AI development, and drug discovery.

Analyst Opinion

As per our analysts, the global gene prediction tools market is set for substantial growth, driven by AI-powered genomics, NGS, and expanding applications in precision medicine. Innovations such as deep learning algorithms, cloud-based genomic analysis, and hybrid prediction models are enhancing gene identification accuracy, accelerating market adoption. Moreover, the rising prevalence of genetic disorders, increasing government-funded genomic research initiatives, and pharmaceutical advancements are fueling demand for these tools.

Despite its promising trajectory, the market faces challenges such as high costs of genomic analysis, data privacy concerns, and the complexity of integrating AI-driven models into clinical settings. Moreover, regulatory hurdles, ethical concerns related to genetic data usage, and the need for specialized expertise pose obstacles to seamless adoption.

However, emerging markets, particularly in Asia-Pacific, are witnessing rapid growth due to increasing biotech investments, large-scale genome sequencing initiatives, and supportive government policies. The continued development of affordable sequencing technologies, cloud-based solutions, and AI-driven analytics is expected to mitigate these challenges, fostering greater accessibility and scalability.